Monte Rosa Therapeutics, Inc. (GLUE) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 7 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for GLUE is $31.75, representing a +81.4% upside from the current price of $17.5. Price targets range from a low of $22.00 to a high of $37.00.
